VLAB: Tapping into the Booming Neuropharma Market

This month's Neuropharmaceutical panel/forum event will spotlight the evolution of Ceregene from concept to clinical trials, and how the company overcame scientific challenges and negotiated critical licensing and partnering deals in its quest to develop the first gene therapy treatment for neurological disorders. Presented by MIT/Stanford Venture Lab (VLAB), the featured guest speaker is Jeffrey Ostrove, President and CEO of Ceregene. Moderated Zack Lynch of NeuroInsights, panelists include: Thorsten Melcher, Saegis Pharmaceuticals; David Summa, Acumen Pharmaceuticals; David Mack, Alta Partners; and Frank Eeckman, Centient Biotech Investor. Please join us as our distinguished panelists share their perspectives on critical strategic issues and opportunities in neuropharmaceutical discovery and development.